BOSTON and LONDON – October 3, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate …
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
BOSTON and LONDON – September 17, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON and LONDON – September 5, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON – September 3, 2025 – Akari Therapeutics, Plc …
[Read more...] about Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
